Slide 1: Cover letter to stock exchanges
Laurus Labs Limited Corporate Office 2"" Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - 500034, Telangana, India T +91 40 39804333 I 2342 0500 I 501 LAURUS Labs F +91 40 3980 4320 Knowledge . Innovation . Excellence April 30, 2020 To To The Corporate Relations Department The Listing D
Slide 2: Q4 & FY20 Investor Presentation
LAURUS LABS LIMITED Q4 & FY20 INVESTOR PRESENTATION April 30, 2020 BSE: 540222 NSE : LAURUSLABS
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Business Snapshot
Business Snapshot - API -FDF Overview • Development, manufacture and sale • Developing and manufacturing oral • Contract development and manufacturing services for of APIs and Advanced Intermediates solid formulations for LMIC, North global pharmaceutical companies and several late stage • Leadershi
Slide 5: Growth Verticals – Diversified Pharma Company
Growth Verticals – Diversified Pharma Company • Leveraging API Synergies for Forward Integration • Targeting various high growth markets like LMIC, US, Canada, & Europe • Therapeutic Focus Areas remains on key segments of ARV, CVS, CNS, PPI & Anti Formulations Diabetic • In FY20 generated revenue of
Slide 6: Formulations Business
Formulations Business
Slide 7: Formulations Strategy – Emerging Markets
Formulations Strategy – Emerging Markets Growth Levers • ARV Tender business from LMIC remains the forefront of our Formulations Strategy. Overview • Formulation Filings are deeply backward Integrated giving further cost advantage compared to peers Participation via – Global Fund tenders, PEPFAR, WH
Slide 8: Formulations Strategy – Developed Markets
Formulations Strategy – Developed Markets Current Filings Status Current Approval Status Therapy US ANDA Europe Canada Therapy US ANDA Europe Canada ARV 15 4 5 Final Anti- Diabetic 3 1 2 Approval 6 5 5 CVS 3 - - Tentative Approval 5 - - CNS 1 1 1 Total 11 5 5 Others 4 - 2 Total 26 6 10 North America
Slide 9: Synthesis Business
Synthesis Business
Slide 10: Synthesis (CDMO) Business Strategy
Synthesis (CDMO) Business Strategy 3851 2946 1618 1946 1010 FY 16 FY 17 FY 18 FY19 FY20 Synthesis Revenue (INR mn) OVERVIEW • State-of-the-art cGMP facilities to manufacture NCEs and Intermediates • Integrated projects from Pre Clinical to Commercial stages • Working with Large Global Innovator Phar
Slide 11: Generic API Business
Generic API Business
Slide 12: Generic APIs Strategy
Generic APIs Strategy • ARV API - Growth in ARV APIs will be driven by • New patients addition • Introduction of new Second Line products • Maintaining Leadership in the existing product portfolio • Large capacity for 2 first line products – Lamivudine & Dolutegravir • Developed Second Line Products
Slide 13: Infrastructure & R&D
Infrastructure & R&D
Slide 14: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 323 reactors with 1,196 Kilo Liters capacit
Slide 15: Manufacturing Facilities at Achutapuram, Vizag
Manufacturing Facilities at Achutapuram, Vizag • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) Unit-II • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be operational by Septemb
Slide 16: Strong R&D Capabilities
Strong R&D Capabilities R&D Centre - Hyd 1,659 1,602 1,338 1,135 853 7.4% 7.1% 5.6% 5.7% 4.8% FY16 FY17 FY18 FY 19 FY 20 R&D Spend % of Revenue 60+ 60 257 26 750+ 50+ Products Filed Patents ANDAs/ NDAs Scientists PhDs commercialized DMFs filed since inception 6&5 116 Patents Final & Tentative grante
Slide 17: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits Laurus’ Philosophy “One Quality Standard for all markets” Regular Inspection at different manufacturing units 2019 USFDA, ANVISA, KFDA, JAZMP – Slovenia We maintain consistent quality, efficiency and product 2018 USFDA, JAZMP - Slovenia safety. 2017 WHO, USFDA, EU (
Slide 18: Financial Performance
Financial Performance
Slide 19: Drivers of Revenue – Division-wise revenue breakup
Drivers of Revenue – Division-wise revenue breakup Total Revenue showed a robust growth of 32% for the quarter (Y-o-Y) 10% 14% 12% 11% 9% & 24% for FY20 (Y-o-Y) 7% 7% 10% Generic FDF business recorded significant growth for the 6% 11% quarter and FY20. • The robust growth was led by higher sales f
Slide 20: Segmental Breakup of Merged Divisions
Segmental Breakup of Merged Divisions Segmental Breakup FY20 Q4 FY20 Q3 FY20 Q2 FY20 Q1 FY20 Q4 FY19 FY 19 (INR mn) ARV API 10,330 2,645 1,981 2,986 2,718 3,153 13,947 HEP – C 533 83 155 183 112 415 1,197 Anti – Viral 10,863 2,728 2,136 3,169 2,830 3,568 15,144 Other API – Ingredients 119 43 14 41 2
Slide 21: Performance Highlights - Abridged Profit & Loss statement
Performance Highlights - Abridged Profit & Loss statement Growth % Growth % Growth % Particulars (INR mn) Q4 FY20 Q4 FY 19 (Q4 FY20 Vs. Q3 FY 20 (Q4 FY20 Vs. FY20 FY19 (FY20 Vs. Q4 FY 19) Q3 FY 20) FY19) REVENUE 8,391 6,352 32.1% 7,296 15.0% 28,317 22,919 23.6% EBITDA 1,934 1,134 70.5% 1,500 28.9% 5
Slide 22: Abridged Balance Sheet
Abridged Balance Sheet As on As on Particulars (INR mn) 31.03.2020 31.03.2019 EQUITY AND LIABILITIES Share capital 1,069 1,064 Reserves and surplus 16,629 14,520 Non-current liabilities 2,882 3,489 Current liabilities 16,923 14,239 Total 37,503 33,312 ASSETS Fixed assets 17,936 17,387 Non-current as
Slide 23: Snapshot of Return Ratios
Snapshot of Return Ratios Pre Tax Return on Capital Return on Equity(2) (%) Total Debt/Equity Ratio (x) Employed(1) (%) 16.5% 16.5% 17.0% 17.4% 1.2x 15.3% 1.1x 14.5% 14.1% 13.7% 12.7% 11.9% 0.7x 0.7x 8.2% 0.6x 0.6x 6.2% FY15 FY16 FY17 FY 18 FY 19 FY 20 FY15 FY16 FY17 FY 18 FY 19 FY 20 FY15 FY16 FY17
Slide 24: Outlook for FY21 & Beyond
Outlook for FY21 & Beyond Healthy Revenue visibility on the Changing business mix to drive Capacity augmentation to result back of robust Order Book growth in better return ratios • Partnership with Global Fund offers higher • Generic FDF segment contributed ~30% • Among top 5 in India in terms of v
Slide 25: Key Milestones
Key Milestones • Investment of INR 3000 mn by • Investment of INR Warburg Pincus • Crossed INR 20 billion of revenue 600 mn by FIL • Incorporated First • Commenced commercial operations • Set up the R&D Capital Subsidiary in USA. • Successfully listed on BSE &NSE from Unit 4 Centre at IKP, Managemen
Slide 26: Management Team
Management Team Mr. Tom Versosky President FDF North America Mr. Raja Ram Iyer SVP - Portfolio Management Mr. V V Ravi kumar Mr. G Venkateshwar Reddy ED &CFO CS & AVP – Legal & Secretarial Dr. Satyanarayana Chava Founder & CEO Mr. Sumeet Sobti VP – SCM Dr. V Uma Maheswer Rao Mr. C. Krishna Chaitanya
Slide 27: Corporate Governance
Corporate Governance Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Dr Lakshmana Rao C V Whole-time Director and Head, Quality Non-Executive Directors Name Background Dr. M. Venu Gop
Slide 28: Ownership Structure
Ownership Structure Corporate Structure Laurus Labs Limited India Laurus Synthesis Sriam Labs Pvt Ltd. Laurus Holdings Ltd. All are 100% Inc. Subsidiaries India UK USA Laurus Generics Laurus Generics Inc. GmbH. USA Germany Shareholding pattern * 32.04% 3.9% 11.3% 1.3% 1.1% 19.6% 5.7% 25.1% Promoter
Slide 29: Awards 2019
Awards 2019 PORTER PRIZE 2019 NATIONAL SAFETY PHARMAEXCIL Laurus Labs won the prestigious Porter Prize 2019. The AWARD AWARD eponymous award was presented to Dr. Satyanarayana Chava, Founder & CEO, Laurus Labs, by Dr. Bibek Debroy, Laurus Labs, Unit 1 & Unit 3 won the Laurus Labs won the Pharmexcil
Slide 30: Fortune 500 Company, Great Place To Work
Laurus Labs is a Fortune 500 Company, Great Place To Work and one of the India’s Best Workplace in 2019 Laurus Labs is certified as Laurus Labs is recognized as Laurus Labs continues to be in the one of the Best Work Places in Fortune 500 Companies List in India “Great Place to Work” for the second
Slide 31: Results Conference Call
Results Conference Call Results conference call on Thursday April 30, 2020 at 4:30 PM IST Details of the conference call are as follows: Timing 4:30 PM IST on Thursday, April 30, 2020 Conference dial-in Universal Dial-In +91 22 6280 1214 India Local access Number +91 7045671221 Available all over In
Slide 32: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thri
Slide 33: Thank You
Thank You